Eating disorders are on the rise. GLP-1s could make things worse.
GLP-1 weight-loss drugs are one of the biggest biotech breakthroughs of the last decade. But to some clinical psychologists, they can represent something more sinister—a potential trigger for eating disorders. A new report suggests that the global incidence of anorexia nervosa and bulimia nervosa shot up between 1990 and 2023—by a whopping 71%. By 2023,…
We haven't written up this one. MIT Tech Review Biotech has the full story — the link below goes straight to it.
